ArticleTherapeutic advances in medical oncology2022

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.

Jingshan Ho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.